Trial Profile
Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Dec 2015
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Gemtuzumab ozogamicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 10 Dec 2015 New trial record